Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
The post-bariatric hypoglycemia market landscape is undergoing a significant transformation, moving beyond traditional dietary modifications and off-label therapies such as acarbose, diazoxide, calcium channel blockers, and somatostatin analogues toward targeted, mechanism-driven treatments. Emerging therapies, including Avexitide (Amylyx Pharmaceuticals), Mizagliflozin (Vogenx), Pasireotide (SIGNIFOR) (Recordati Group), Imapextide (MBX 1416) (MBX Biosciences), and others, are attracting considerable interest for their potential to reduce hypoglycemic episodes, enhance glycemic control, and address the underlying pathophysiological mechanisms of PBH.
LAS VEGAS, July 7, 2026 /PRNewswire/ -- Recently published Post-Bariatric Hypoglycemia Market Insights report includes a comprehensive understanding of current treatment practices, post-bariatric hypoglycemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Post-Bariatric Hypoglycemia Market Summary
Discover what is the future of the post-bariatric hypoglycemia treatment market @ https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
Key Factors Driving the Growth of the Post-Bariatric Hypoglycemia Market
Sharad Chandra Vinayak, Assistant Project Manager of Forecasting at DelveInsight, said that due to the limited pipeline, mizagliflozin and avexitide might face less competition among branded drugs due to the novel MoA and can flourish in the market.
Post-Bariatric Hypoglycemia Market Analysis
Post-Bariatric Hypoglycemia Competitive Landscape
Some of the PBH drugs under development include Avexitide (Amylyx Pharmaceuticals), Mizagliflozin (Vogenx), Pasireotide (SIGNIFOR) (Recordati Group), Imapextide (MBX 1416) (MBX Biosciences), CFTX-2034 (Confo Therapeutics), AMX0318 (Amylyx Pharmaceuticals and Gubra), Efpegerglucagon (Hanmi), and others.
Amylyx Pharmaceuticals' Avexitide (exendin 9-39) is a 31-amino acid peptide that selectively antagonizes glucagon-like peptide-1 (GLP-1) receptors, thereby reducing inappropriate pancreatic insulin secretion and mitigating both fasting and postprandial hypoglycemia in patients with post-bariatric hypoglycemia (PBH). The therapy has been granted both Breakthrough Therapy Designation and Orphan Drug Designation by the U.S. FDA for the treatment of hyperinsulinemic hypoglycemia, a hallmark feature of PBH.
Vogenx's Mizagliflozin is an orally administered, minimally absorbed sodium-glucose cotransporter 1 (SGLT1) inhibitor designed to address the underlying pathophysiology of PBH. Patients with PBH exhibit elevated intestinal SGLT1 activity, leading to rapid glucose absorption, exaggerated postprandial glycemic excursions, and excessive insulin secretion. By inhibiting SGLT1-mediated glucose uptake in the intestine, mizagliflozin delays and reduces postprandial glucose absorption, thereby moderating insulin release and lowering the risk of hypoglycemic episodes. The therapy is currently being evaluated in a Phase IIb clinical trial.
MBX Biosciences' Imapextide (MBX 1416) is a long-acting GLP-1 receptor antagonist peptide developed to reduce excessive insulin secretion and prevent recurrent hypoglycemic events in patients with PBH. Built on MBX Biosciences' Precision Endocrine Peptide platform, the therapy is designed to provide sustained GLP-1 receptor blockade with less frequent dosing, potentially improving patient convenience and treatment adherence. Imapextide has also received U.S. FDA Orphan Drug Designation for the treatment of post-bariatric hypoglycemia.
The anticipated launch of these emerging therapies are poised to transform the post-bariatric hypoglycemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the post-bariatric hypoglycemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which pipeline drugs could transform post-bariatric hypoglycemia treatment @ Post-Bariatric Hypoglycemia Drugs
Recent Developments in the Post-Bariatric Hypoglycemia Market
What is Post-Bariatric Hypoglycemia?
Post-Bariatric Hypoglycemia (PBH) is a metabolic complication that occurs in some individuals following bariatric procedures, particularly Roux-en-Y gastric bypass and, less commonly, sleeve gastrectomy. It is characterized by recurrent episodes of low blood glucose, typically occurring 1–3 hours after meals, due to an exaggerated insulin response triggered by the rapid delivery of nutrients into the small intestine. Common symptoms include sweating, tremors, palpitations, dizziness, confusion, blurred vision, and, in severe cases, seizures or loss of consciousness, which can significantly impair quality of life. Although the exact pathophysiology is multifactorial, altered gut hormone secretion, especially increased glucagon-like peptide-1 (GLP-1) activity, along with enhanced insulin sensitivity and impaired counter-regulatory mechanisms, are considered key contributors. The condition is initially managed through dietary modifications, such as consuming frequent low-glycemic meals rich in protein and fiber, while pharmacological therapies and, in rare refractory cases, surgical interventions may be required for persistent symptoms.
Post-Bariatric Hypoglycemia Epidemiology Segmentation
The post-bariatric hypoglycemia epidemiology section provides insights into the historical and current post-bariatric hypoglycemia patient pool and forecasted trends for the leading markets. The observed female predominance and earlier onset of PBH highlight the importance of early postoperative monitoring, timely diagnosis, individualized nutritional management, and targeted therapeutic interventions to reduce hypoglycemic complications and improve long-term patient outcomes.
The post-bariatric hypoglycemia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Post-Bariatric Hypoglycemia Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Post-Bariatric Hypoglycemia Market CAGR
16.4 %
Post-Bariatric Hypoglycemia Market Size in 2025
USD 470 Million
Key Post-Bariatric Hypoglycemia Companies
Amylyx Pharmaceuticals, Vogenx, Recordati Group, MBX Biosciences, Confo Therapeutics, Gubra, Hanmi, and others
Key Post-Bariatric Hypoglycemia Therapies
Avexitide, Mizagliflozin, Pasireotide (SIGNIFOR), Imapextide (MBX 1416), CFTX-2034, AMX0318, Efpegerglucagon, and others
Scope of the Post-Bariatric Hypoglycemia Market Report
Download the report to understand the top emerging therapies in post-bariatric hypoglycemia @ Post-Bariatric Hypoglycemia Market Analysis
Table of Contents
1
Post-Bariatric Hypoglycemia Market Key Insights
2
Post-Bariatric Hypoglycemia Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
Post Bariatric Hypoglycemia (PBH) Market Overview at a Glance
6.1
Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2
Market Share (%) Distribution of PBH By Therapies in the 7MM, in 2025
6.3
Market Share (%) Distribution of PBH By Therapies in the 7MM, in 2036
7
Disease Background and Overview of Post-Bariatric Hypoglycemia (PBH)
7.1
Introduction
7.2
Hypoglycemia after Gastric Bypass Surgery
7.3
Etiology of PBH
7.4
Risk Factors and Surgical Associations in PBH
7.5
Pathophysiology of PBH
7.6
Diagnosis
7.7
Differential Diagnosis
7.8
Diagnostic Guidelines
8
Treatment
8.1
Dietary and behavioural modification
8.2
Pharmacotherapy
8.3
Surgical or endoscopic options
8.4
Treatment Guidelines
9
Epidemiology and Patient Population of Post-Bariatric Hypoglycemia (PBH)
9.1
Key Findings
9.2
Assumptions and Rationale
9.3
Total Prevalent Cases of PBH in the 7MM
9.4
The United States
9.4.1
Total Prevalent Cases of Post-Bariatric Hypoglycemia (PBH) in the US
9.4.2
Total Prevalent Cases of Post-Bariatric Hypoglycemia (PBH) by Type of Bariatric Surgery in the US
9.4.3
Gender-specific Cases of Post-Bariatric Hypoglycemia (PBH) in the US
9.4.4
Type-specific Cases of Post-Bariatric Hypoglycemia (PBH) in the US
9.4.5
Total Treated Cases of Post-Bariatric Hypoglycemia (PBH) in the US
9.5
EU4 and the UK
9.6
Japan
10
Patient Journey of Post-Bariatric Hypoglycemia (PBH)
11
Emerging PBH Drugs
11.1
Emerging Competitive Landscape of Post-Bariatric Hypoglycemia (PBH)
11.2
Avexitide: Amylyx Pharmaceuticals
11.2.1
Drug Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trials Information
11.2.4
Analyst's Views
11.3
Mizagliflozin: Vogenx
List to be continued in the report
12
Post Bariatric Hypoglycemia Market: 7MM Analysis
12.1
Key Findings
12.2
Market Outlook of Post Bariatric Hypoglycemia (PBH)
12.3
Key Post-Bariatric Hypoglycemia Market Forecast Assumptions
12.4
Conjoint Analysis of Post-Bariatric Hypoglycemia (PBH)
12.5
Total Market Size of PBH in the 7MM
12.6
Total Market Size of PBH by Therapies in the 7MM
12.7
The United States Post-Bariatric Hypoglycemia Market
12.7.1
Total Market Size of PBH in the United States
12.7.2
Total Market Size of PBH by Therapies in the United States
12.8
EU4 and the UK Post-Bariatric Hypoglycemia Market
12.9
Japan Post-Bariatric Hypoglycemia Market
13
Unmet Needs of Post Bariatric Hypoglycemia (PBH)
14
SWOT Analysis of Post Bariatric Hypoglycemia (PBH)
15
KOL Views of Post Bariatric Hypoglycemia (PBH)
16
Market Access and Reimbursement of Post-Bariatric Hypoglycemia (PBH)
16.1
The United States
16.2
EU4 and the UK
16.3
Japan
16.4
Summary and comparison of Market Access and Pricing Policy Developments in 2025
16.5
Market Access and Reimbursement of PBH Therapies
17
Bibliography
18
Post-Bariatric Hypoglycemia Market Report Methodology
Related Reports
GLP Agonists Market
GLP Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GLP agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.
GLP Agonists Clinical Trial Analysis
GLP Agonists Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GLP agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.
SGLT Inhibitors Market
SGLT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SGLT inhibitors companies, including Youngene Therapeutics, Jeil Pharmaceuticals, TheracosBio, Eli Lilly, and others.
Non-alcoholic Fatty Liver Disease Market
Non-alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NAFLD companies, including as MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP